Navigation Links
MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Date:8/26/2009

Pain relieving effects of MoxDuo(TM) IR are dose-related with a better safety profile than Percocet(R) in patients with post-operative pain following total knee replacement

SYDNEY, Australia and BEDMINSTER, N.J., Aug. 26 /PRNewswire/ -- QRxPharma Limited (ASX: QRX) and (OTCQX: QRXPY) announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery. When compared at equianalgesic doses with Percocet(R), the second most widely prescribed opioid in the US, MoxDuo(TM) IR demonstrated greater overall tolerability with substantially fewer incidences of moderate to severe nausea, vomiting, constipation, and hypotension than Percocet(R). Scheduled for launch in 2011, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US.

"This study serves to reinforce earlier clinical findings that showed improved tolerability and again demonstrates the value of our Dual-Opioid platform as MoxDuo IR opens the therapeutic window for treating patients suffering from acute post-surgical pain," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We believe the MoxDuo product portfolio, including immediate release, controlled release and intravenous formulations, will significantly improve patient care, providing equal or better analgesia with fewer and/or less intense side effects than current standards of care."

MoxDuo(TM) IR is the first patented analgesic product in the world that consists of two opioid drugs (a fixed ratio of morphine and oxycodone). While many analgesic combination drugs exist that contain opioids with mild pain drugs such as aspirin, ibuprofen or acetaminophen, combination products such as Perc
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
2. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
3. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
4. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
5. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
6. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
7. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
8. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
9. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
10. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... ... 2015 , ... India Network Foundation, a non-profit US-based sponsor ... summarizes all available plans, plan maximums, pre-existing condition coverage limits and deductible in ... Network members make an informed decision regarding the care they want for their ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence ... is unique to the Lake Orion area. This program is one of the ... WEmovestrong’s weight management program will incorporate group fitness and nutritional consultations to help ...
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a ... Corporate Communications. In this capacity, Michael will provide strategic leadership for CareSource’s marketing, ... in consumer-focused programs that have contributed to the company’s rapid growth. As the ...
(Date:8/31/2015)... ... ... The Bay Pines VA Healthcare System (VAHCS) remains focused on ... doctors and nurses and expanding existing facilities and services. Spine surgery will soon ... Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine surgery ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease and ... emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore ... largely untreatable - with mostly palliative treatments only - and now we have ...
Breaking Medicine News(10 mins):Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3
... drug that kills chronic leukemia cells., The drug targets a ... leukemia cells., This study showed unexpectedly that CD37 helps regulate ... and how it might be improved. COLUMBUS, ... role for a molecule on the surface of the immune ...
... their seventies who exercise and eat healthy amounts of fruits ... published in the Journal of the American Geriatrics Society ... Johns Hopkins University studied 713 women aged 70 to 79 ... Studies. This study was designed to evaluate the causes and ...
... Granada has concluded that most immigrant women who give ... psychological treatment after giving birth to help them overcome ... or psychoticism. These disorders are caused by "the stress ... This is a very stressful moment in women,s life ...
... , WEDNESDAY, May 30 (HealthDay News) -- ,The ancient ... syndrome, a small new study suggests. Metabolic syndrome is ... (a type of fat found in the blood), high fasting ... the risk of diabetes and heart disease. Bloodletting was ...
... 13 for SLEEP 2012, the premier event for sleep ... with the best clinical practices. SLEEP 2012, the 26th ... is being held at the John B. Hynes Veterans Memorial ... exhibition hall focused solely on sleep medicine and sleep research. ...
... HealthDay Reporter , TUESDAY, May 29 (HealthDay News) -- ... more likely to eat better and watch less TV if ... and get reminders from coaches. It,s not clear how ... why it might work, but the study lead author said ...
Cached Medicine News:Health News:Researchers identify a 'life-and-death' molecule on chronic leukemia cells 2Health News:Exercise and a healthy diet of fruits and vegetables extends life expectancy in women in their 70s 2Health News:Immigrant women giving birth in Spain suffer 'great stress,' a study warns 2Health News:Could Bloodletting Ease Heart Risks for the Obese? 2Health News:SLEEP 2012 presents latest in sleep medicine and research June 11-13 in Boston 2Health News:Cash, Coaching May Boost Healthy Living 2Health News:Cash, Coaching May Boost Healthy Living 3
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: